Holen Sie sich die Stockscreener-App
13.06
19.27%
2.11
Handel nachbörslich:
13.00
-0.06
-0.46%
Schlusskurs vom Vortag:
$10.95
Offen:
$12.325
24-Stunden-Volumen:
5.89M
Relative Volume:
3.01
Marktkapitalisierung:
$1.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-27.79
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
+13.66%
1M Leistung:
+31.52%
6M Leistung:
-27.04%
1J Leistung:
+14.26%
1-Tages-Spanne:
$12.20
$13.14
1-Wochen-Bereich:
$10.85
$13.14
52-Wochen-Spanne:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
13.06 | 1.08B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Yahoo Finance
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Approval Expands Neffy Allergy Market Reach - Sahm
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
What drives ARS Pharmaceuticals Inc stock priceVolatility Index Analysis & Access High Yield Alerts - earlytimes.in
ARS Pharma’s neffy nasal spray approved in China... - The Pharma Letter
The Technical Signals Behind (SPRY) That Institutions Follow - Stock Traders Daily
ARS Pharmaceuticals Stock Pre-Market (+4.4%) : 'neffy' Nasal Spray Approved in China - Trefis
Is ARS Pharmaceuticals a buy? - Cantech Letter
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - simplywall.st
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg - Yahoo Finance
China approves first community use epinephrine nasal spray for allergies By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 3.4%Time to Buy? - MarketBeat
ARS Pharma Receives Approval For Neffy In China, Expanding Global Reach - Nasdaq
ARS Pharmaceuticals Wins China Approval for First Community-Use Epinephrine for Allergic Reactions - MarketScreener
China approves first community use epinephrine nasal spray for allergies - Investing.com
ARS Pharmaceuticals' neffy Approved as First Epinephrine Nasal Spray for Out-of-Hospital Use in China - Quiver Quantitative
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - The Manila Times
Needle-free allergy rescue spray cleared in China for home use - Stock Titan
ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Trading Systems Reacting to (SPRY) Volatility - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Potential 152% Upside Captivates Investors - DirectorsTalk Interviews
Is ARS Pharmaceuticals Inc. stock cheap at current valuationJuly 2025 Highlights & Reliable Volume Spike Alerts - Улправда
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 7.9% HigherWhat's Next? - MarketBeat
Can ARS Pharmaceuticals Inc. stock hit record highs againJuly 2025 Setups & Verified Trade Idea Suggestions - Bölüm Sonu Canavarı
What insider trading reveals about ARS Pharmaceuticals Inc. stockMarket Performance Report & Daily Stock Trend Watchlist - Улправда
Is ARS Pharmaceuticals Inc. stock near bottom after declineMarket Sentiment Summary & High Conviction Investment Ideas - ulpravda.ru
ARS Pharmaceuticals Earnings Notes - Trefis
Avoiding Lag: Real-Time Signals in (SPRY) Movement - news.stocktradersdaily.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 6.3%Time to Buy? - MarketBeat
Is ARS Pharmaceuticals Inc a good long term investmentStock Correlation Metrics & Investment Recommendations You Can Trust - earlytimes.in
Next Century Growth Investors LLC Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Ardsley Advisory Partners LP Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How ARS Pharmaceuticals Inc. stock reacts to global recession fearsJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - Newser
Why ARS Pharmaceuticals Inc. stock is favored by pension fundsPortfolio Update Report & Safe Capital Investment Plans - Newser
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8.1%Here's What Happened - MarketBeat
Is ARS Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 Momentum & Short-Term Swing Trade Alerts - Newser
Discipline and Rules-Based Execution in SPRY Response - news.stocktradersdaily.com
ARS Pharmaceuticals, Inc. $SPRY Shares Bought by Geode Capital Management LLC - MarketBeat
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts - Yahoo Finance
Steward Partners Investment Advisory LLC Raises Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Franklin Resources Inc. Sells 28,789 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes $1.77 Million Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
ARS Pharmaceuticals, Inc. to Participate in Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
ARS Pharmaceuticals (NASDAQ: SPRY) in fireside chat at Piper Sandler 37th Conference - Stock Titan
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):